ACADIA Pharmaceuticals Inc. reiterated earnings guidance for the full year 2024. For the year, the company expects DAYBUE net product sales guidance in the range of $370 million to $420 million. NUPLAZID net product sales guidance in the range of $560 million to $590 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.25 USD | +0.99% | +0.93% | -51.36% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.36% | 249.48Cr | |
+47.96% | 5.46TCr | |
-6.25% | 3.99TCr | |
+37.07% | 3.88TCr | |
+13.79% | 2.69TCr | |
-11.17% | 2.62TCr | |
-21.17% | 1.88TCr | |
+25.49% | 1.22TCr | |
+1.00% | 1.22TCr | |
+26.03% | 1.19TCr |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.
- Acadia Pharmaceuticals Inc. Reiterates Earnings Guidance for the Full Year 2024